Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

The OncFive: Top Oncology Articles for the Week of 10/5

October 11th 2025

The FDA approved adjuvant cemiplimab in cutaneous squamous cell carcinoma, issued a CRL to dasatinib in chronic myeloid leukemia, and more.

Dr Sweis on the Mechanism of Action of XmAb819 in RCC

October 10th 2025

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

RCC Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 10th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights renal cell carcinoma.

Inside the Most Anticipated Genitourinary Cancer Abstracts: What to Watch at ESMO 2025

October 8th 2025

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

Dr Runcie on the Mechanism of Action of XmAb30819 in ccRCC

October 6th 2025

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.

Bevacizumab Plus Erlotinib Shows Antitumor Activity in Advanced Papillary Renal Cell Carcinoma

October 6th 2025

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.

Real-World Study Demonstrates Safety and Efficacy of Avelumab/Axitinib in Advanced RCC

October 3rd 2025

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

Dr Sweis on Targeting ENPP3 in Clear Cell Renal Cell Carcinoma

October 2nd 2025

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

Pembrolizumab Plus Chemotherapy Shows Preliminary Activity in Advanced Penile Cancer

October 2nd 2025

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

Dual-Binding XmAb30819 Shows Strong Specificity in ENPP3-Positive RCC

October 1st 2025

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

Poll Results Spotlight Key GU Cancer Abstracts Driving Anticipation Ahead of ESMO 2025

September 26th 2025

OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Timing of Real-World Belzutifan-Related AEs Varies Between VHL-Associated Tumors and Sporadic RCC

September 25th 2025

Real-world data highlighted differences in the timing and severity of belzutifan-related toxicities in VHL-associated tumors and sporadic RCC.

Poll: Vote on the Top Lung, GU Cancer Abstracts to Watch at ESMO 2025

September 22nd 2025

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Dr Pal on the Rationale for Evaluating Atezolizumab in High-Risk Localized RCC

September 18th 2025

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Dr Chehrazi-Raffle on the TiNivo-2 Study of Tivozanib With/Without Nivolumab in mRCC

September 16th 2025

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

Dr Chahoud on the Safety of ALLO-316 in Advanced ccRCC

September 16th 2025

Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.

Dr Chahoud on ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma

September 9th 2025

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Zanzalintinib Plus Nivolumab Generates Early Antitumor Activity in Untreated Advanced ccRCC

September 3rd 2025

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.